Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy

World Journal of Gastroenterology

Volumn 11, Issue 35, 2005, Pages 5521-5524

  Ocker, Matthias ^a   Ganslmayer, Marion ^a   Zopf, Steffen ^a   Gahr, Susanne ^a   Janson, Christopher ^a   Hahn, Eckhart G ^a   Herold, Christoph ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aminopyrine breath test; Galactose elimination capacity; Hepatitis C; Indocyanine green clearance; Interferon; Ribavirin; Sorbitol clearance

Indexed keywords

AMINOPHENAZONE; AMINOTRANSFERASE; ANTIVIRUS AGENT; GALACTOSE; INDOCYANINE GREEN; INTERFERON; PEGINTERFERON; RIBAVIRIN; SORBITOL; VIRUS RNA;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CYTOSOL; LIVER FUNCTION TEST; LIVER MICROSOME; LIVER PERFUSION; MALE; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 28044446099     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i35.5521     Document Type: Article

References (27)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237
2. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; S1: S31-38
3. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. International Hepatitis Interventional Therapy Group. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-693
4. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
7. Shiffman ML. Management of patients with chronic hepatitis C virus infection and previous nonresponse. Rev Gastroenterol Disord 2004; S1: S22-30
8. Herold C, Heinz R, Radespiel-Troeger M, Schneider HJ, Hahn EG, Schuppan D. Quantitative liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001; 21: 26-30
9. Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, Marchesini G, Ruol A. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991; 36: 1197-1203
10. Merkel C, Marchesini G, Fabbri A, Bianco S, Bianchi G, Enzo E, Sacerdoti D, Zoli M, Gatta A. The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology 1996; 24: 820-823
11. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology 1991; 14: 504-510
12. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260-265
13. Herold C, Regn S, Ganslmayer M, Ocker M, Hahn EG, Schuppan D. Can quantitative testing of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002; 47: 2669-2673
14. Herold C, Ganslmayer M, Ocker M, Zopf S, Gailer B, Hahn EG, Schuppan D. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003; 18: 445-449
15. Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C) aminopyrine. Ann Intern Med 1975; 83: 632-638
16. Tygstrup N, Andersen P, Thompsen BL. Prognostic evaluation in alcoholic cirrhosis. Acta medica Scandinavia Suppl 1986; 703: 149-153
17. Zeeh J, Lange H, Bosch J, Pohl S, Loesgen H, Eggers R. Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 1988; 95: 749-759
18. Leevy CM, Mendenhall CL, Lesko We, Howard MM. Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962; 41: 1169-1179
19. Horsmans Y, Brenard R, Geubel AP. Short report: interferon-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther 1994; 8: 353-355
20. Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, Male PJ, Renner EL, Solioz M, Schmid M, Zimmermann A. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. J Hepatol 1996; 25: 275-282
21. Saunders JB, Lewis KO, Paton A. Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test. Gastroenterology 1980; 79: 112-114
22. Saunders JB, Wright N, Lewis KO. Predicting outcome of paracetamol poisoning by use 14C-aminopyrine breath test. Br Med J 1980; 280: 279-80
23. Giannini E, Fasoli A, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Polegato S, Fumagalli A, Testa R. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-725
24. Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976; 17: 959-964
25. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406
26. Moradpour D, Brass V, Gosert R, Wölk B, Blum HE. Hepatitis C: molecular virology and antiviral targets. Trends Mol Med 2002; 8: 476-482
27. Andersen V, Sonne J, Court-Payen M, Sletting S, Prip A, Molholm-Hansen J. Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment. Scand J Gastroenterol 1999; 34: 618-622